Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis

NCT03235752 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Active Ulcerative Colitis

Interventions

DRUG: TJ301 300mg
DRUG: TJ301 600mg
DRUG: Placebo

Sponsor

I-Mab Biopharma HongKong Limited